The Patent Finder

Terms ending in 2037

Sandoz AG

Every in-force patent on Sandoz AG's record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 11,292,833Selective Reduction of Cysteine Residues in IL-17 Antibodies
In force
 · High confidence
Novartis Pharma AGIn forceHigh confidence
US 10,842,782Storage Stable Composition Comprising Rifaximin Alpha
In force
 · High confidence
Sandoz AGIn forceHigh confidence
US 10,576,065Pharmaceutical Composition Containing Rifaximin Alpha & Delta
In force
 · High confidence
Sandoz AGIn forceHigh confidence
US 10,975,029Crystalline Eravacycline Bis-Hydrochloride
In force
 · High confidence
Sandoz AGIn forceHigh confidence
US 11,124,513Avibactam Free Acid
In force
 · High confidence
Sandoz AGIn forceHigh confidence
5 of 5 patents shown. Soonest term end first, then patent number.
4 of these are in force and held by Sandoz AG.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited